Wettstein Marian S, Buser Lorenz, Hermanns Thomas, Roudnicky Filip, Eberli Daniel, Baumeister Philipp, Sulser Tullio, Wild Peter, Poyet Cédric
Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
Dis Markers. 2015;2015:785461. doi: 10.1155/2015/785461. Epub 2015 Oct 12.
CD73 is a membrane associated 5'-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course.
Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS).
High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors (n = 158) was significantly associated with longer PFS (HR: 0.228; p = 0.047) in univariable Cox regression analysis.
High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.
CD73是一种膜相关的5'-核苷酸酶，已被提出作为多种实体瘤的预后生物标志物。本研究的目的是评估一组原发性膀胱癌患者中CD73的表达情况，及其与临床病理特征和疾病进程的相关性。
在组织芯片上对174例原发性尿路上皮癌患者的组织样本进行免疫组织化学评估。通过列联分析评估CD73表达与回顾性获得的临床病理数据之间的相关性。进行生存分析，以研究在pTa和pT1肿瘤亚组中CD73对无进展生存期（PFS）的预测价值。
46例（26.4%）患者中发现高CD73表达，且与较低分期、较低分级、较少原位癌及较低的Ki-67增殖指数显著相关。在单变量Cox回归分析中，pTa和pT1肿瘤亚组（n = 158）中的高CD73免疫反应性与较长的PFS显著相关（HR：0.228；p = 0.047）。
高CD73免疫反应性与良好的临床病理特征相关。此外，它可预测pTa和pT1肿瘤亚组中更好的预后，因此可作为选择预后良好患者的额外工具。
